Patents by Inventor Marc D. Better

Marc D. Better has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5843685
    Abstract: The invention is directed to a chimeric immunoglobulin that recognizes the human tumor antigen bound by antibody ING-1, its production, and use.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Arnold H. Horwitz, Randy R. Robinson, Shau-Ping Lei, Changtung Paul Chang
  • Patent number: 5837491
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: May 13, 1996
    Date of Patent: November 17, 1998
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
  • Patent number: 5756699
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 26, 1998
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
  • Patent number: 5744580
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 28, 1998
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
  • Patent number: 5621083
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: April 15, 1997
    Assignee: XOMA Corporation
    Inventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
  • Patent number: 5576184
    Abstract: Gene expression elements and their use in production of chimeric antibodies with human constant regions and murine variable regions, and mouse human chimeric antibodies having specificity to human tumor cells, methods of their production, and their use.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: November 19, 1996
    Assignee: Xoma Corporation
    Inventors: Marc D. Better, Arnold H. Horwitz, Randy R. Robinson, Shau-Ping Lei, Changtung P. Chang
  • Patent number: 5416202
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) such as gelonin and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
    Type: Grant
    Filed: December 9, 1992
    Date of Patent: May 16, 1995
    Assignee: XOMA Corporation
    Inventors: Susan L. Bernhard, Marc D. Better, Steve F. Carroll, Julie A. Lane, Shau-Ping Lei
  • Patent number: 5376546
    Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins and analogs thereof having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. Preferred analogs according to the present invention are analogs of Type I ribosome-inactivating proteins (1) having a cysteine available for intermolecular disulfide bonding located at an amino acid position corresponding to a position not naturally available for intermolecular disulfide bonding in the Type I ribosome-inactivating protein and corresponding to a position on the surface of ricin A-chain in its natural conformation and (2) retaining ribosome-inactivating activity of the Type I ribosome-inactivating protein. The RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents and, more specifically, as components of immunotoxins.
    Type: Grant
    Filed: June 19, 1992
    Date of Patent: December 27, 1994
    Assignee: Xoma Corporation
    Inventors: Susan L. Bernhard, Marc D. Better, Steve F. Carroll, Julie A. Lane